From: Metabolic syndrome in rheumatoid arthritis: case control study
 | JC 2009 | IDF (2005) | NCEP ATP III 2004 | NCEP ATP III (2001) | EGIR 1999 | WHO 1998 |
---|---|---|---|---|---|---|
Number of criteria | Three or more of: | And two or more of †: | Three or more of: | Three or more of: | And two or more of †: | And two or more of †: |
Obesity | Population- and country-specific definitions * | WC ≥ 94 cm men, WC ≥ 80 cm women | WC ≥ 102 cm (men), WC ≥ 88 cm (women) | WC ≥ 102 cm (men), WC ≥ 88 cm (women) | WC ≥ 94 cm (men, WC ≥ 80 cm (women) | BMI > 30 and/or WHR > 0.9 (men), WHR > 0.85 (women) |
Blood Pressure mmhg | ≥ 130/85 or treatmen | ≥130/≥85 or treatment | ≥ 130/85 or treatment | ≥ 130/85 or treatment | ≥ 140/90 | ≥ 140/90 |
Dyslipidaemia:HDL-C | ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment | ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment | ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment | ≥ 40 mg/dL (1.03 mmol/L) in men or ≥ 50 mg/dL (1.29 mmol/L) in women | ≥ 39 mg/dL (1.0 mmol/L) or treatment | ≥ 35 mg/dL (0.9 mmol/L) in men or ≥ 39 mg/dL (≥ 1.0 mmol/L) in women |
Triglycerides | ≥150 mg/dL (1.7 mmol/L) or treatment | ≥150 mg/dL (1.7 mmol/L) or treatment | ≥150 mg/dL (1.7 mmol/L) or treatment | ≥150 mg/dL (1.7 mmol/L) | ≥150 mg/dL (1.7 mmol/L) | ≥178 mg/dL (2.0 mmol/L) or treatment |
Glucose intolerance or fasting plasma glucose | ≥100 mg/dL (5.6 mmol/L) or T2D | ≥100 mg/dL (5.6 mmol/L) or T2D | ≥100 mg/dL (5.6 mmol/L) or T2D | ≥110 mg/dL (6.1 mmol/L) | ≥110 mg/dL (6.1 mmol/L) | ≥110 mg/dL (6.1 mmol/l), DM, IGT, IR |